Show simple item record

dc.contributorUniversitat Ramon Llull. IQS
dc.contributor.authorFornaguera Puigvert, Cristina
dc.contributor.authorBorrós i Gómez, Salvador
dc.contributor.authorGarcía-Fernández, Coral
dc.date.accessioned2022-03-01T19:41:56Z
dc.date.accessioned2023-07-13T05:45:09Z
dc.date.available2022-03-01T19:41:56Z
dc.date.available2023-07-13T05:45:09Z
dc.date.issued2020-06
dc.identifier.urihttp://hdl.handle.net/20.500.14342/1074
dc.description.abstractNon-small cell lung cancer (NSCLC) remains the most common cause of cancer-related mortality. The heterogeneous nature of this disease hinders its diagnosis and treatment, requiring continuous advances in research aiming to understand its intricate nature. Consequently, the retrospective analysis of conventional therapies has allowed the introduction of novel tools provided by nanotechnology, leading to considerable improvements in clinical outcomes. Furthermore, the development of novel immunotherapies based on the recently understood interaction of the immune system with the tumor highlights the real possibility of definitively treating NSCLC from its early stages. Novel engineering approaches in nanomedicine will enable to overcome the intrinsic limits of conventional and emerging therapies regarding off-site cytotoxicity, specificity, resistance mechanisms, and administration issues. The convergence point of these therapies with nanotechnology lays the foundation for achieving currently unmet needs.eng
dc.format.extent26 p.cat
dc.language.isoengcat
dc.publisherMDPIcat
dc.relation.ispartofCancers. Vol.12, n.6 (2020), 1609cat
dc.rightsAttribution 4.0 International
dc.rights© L'autor/a
dc.rights.urihttp://creativecommons.org/licenses/by/4.0/
dc.sourceRECERCAT (Dipòsit de la Recerca de Catalunya)
dc.subject.otherPulmons--Càncercat
dc.subject.otherImmunoteràpiacat
dc.subject.otherNanomedicinacat
dc.subject.otherVacunes contra el càncercat
dc.subject.otherQuimioteràpiacat
dc.subject.otherNon-small cell lung cancercat
dc.subject.otherImmunotherapiescat
dc.subject.otherNanomedicinecat
dc.subject.otherCancer vaccinecat
dc.subject.otherChemotherapycat
dc.titleNanomedicine in non-small cell lung cancer: from conventional treatments to immunotherapycat
dc.typeinfo:eu-repo/semantics/articlecat
dc.typeinfo:eu-repo/semantics/publishedVersioncat
dc.rights.accessLevelinfo:eu-repo/semantics/openAccess
dc.embargo.termscapcat
dc.subject.udc616
dc.identifier.doihttps://doi.org/10.3390/cancers12061609cat
dc.relation.projectIDinfo:eu-repo/grantAgreement/SUR del DEC/SGR/SGR 2017 1559cat
dc.relation.projectIDinfo:eu-repo/grantAgreement/MCIU/PN I+D/RTI2018-094734-B-C22cat


Files in this item

 

This item appears in the following Collection(s)

Show simple item record

Attribution 4.0 International
Except where otherwise noted, this item's license is described as http://creativecommons.org/licenses/by/4.0/
Share on TwitterShare on LinkedinShare on FacebookShare on TelegramShare on WhatsappPrint